# Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

> **NCT05730283** · PHASE2 · RECRUITING · sponsor: **Kevin Winthrop** · enrollment: 105 (estimated)

## Conditions studied

- Ototoxicity, Drug-Induced

## Interventions

- **DRUG:** ORC-13661
- **DRUG:** ORC-13661
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05730283
- **Lead sponsor:** Kevin Winthrop
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-02-29
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730283, "Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT05730283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*